Inclusion Of Cost Effectiveness In Licensing Requirements Of New Drugs: The Fourth Hurdle

Autor:	Taylor, R. S., Drummond, M. F., Salkeld, G., Sullivan, S. D.
Zdroj:	BMJ: British Medical Journal, 2004 Oct . 329(7472), 972-975.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/25469311 Zobrazit plný text záznamu